Press Releases
Dec 4, 2020
Summary ToggleIntellia Therapeutics Announces Closing of $201 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass. , Dec. 04, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , announced today the closing of an underwritten public offering of
Dec 1, 2020
Summary ToggleIntellia Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass. , Dec. 01, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , announced today the pricing of an underwritten public offering of
Nov 30, 2020
Summary ToggleIntellia Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. , Nov. 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , announced today that it has commenced an underwritten public
Nov 11, 2020
Summary ToggleIntellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease Treatments
Funding from the Bill and Melinda Gates Foundation to develop safe, scalable and accessible non-viral treatments for sickle cell patients CAMBRIDGE, Mass. , Nov. 11, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced that it has received a grant from the Bill and Melinda
Nov 9, 2020
Summary ToggleIntellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis
NTLA-2001: First single-course therapy that potentially halts and reverses ATTR progression First-ever in vivo CRISPR treatment delivered intravenously to a patient
Nov 5, 2020
Summary ToggleIntellia Therapeutics Announces Third Quarter 2020 Financial Results
On track to dose first patient by year-end with NTLA-2001 for the treatment of transthyretin amyloidosis (ATTR) , following regulatory authorization to initiate Phase 1 clinical trial Anticipate s submit ting an IND or IND-equivalent for lead TCR-T cell therapy, NTLA-5001 for the treatment of
Oct 29, 2020
Summary ToggleIntellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2020 Earnings and Company Updates
CAMBRIDGE, Mass. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present its third quarter 2020 financial results and operational
Oct 19, 2020
Summary ToggleIntellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR)
NTLA-2001: First single-course therapy that potentially halts and reverses ATTR On track to dose first patient by year-end with a systemically delivered CRISPR/Cas9-based therapy CAMBRIDGE, Mass. , Oct. 19, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.
Oct 7, 2020
Summary ToggleIntellia Therapeutics Congratulates Co-Founder Jennifer Doudna On Winning the 2020 Nobel Prize in Chemistry for Inventing the Revolutionary CRISPR/Cas9 Genome Editing Technology
CAMBRIDGE, Mass. , Oct. 07, 2020 (GLOBE NEWSWIRE) -- Today, Jennifer Doudna , Ph.D., one of Intellia Therapeutics , Inc.’s scientific co-founders, was awarded the 2020 Nobel Prize in Chemistry for the development of the CRISPR/Cas9 genome editing technology. Dr.
Oct 5, 2020
Summary ToggleIntellia Therapeutics Names John F. Crowley to Board of Directors
CAMBRIDGE, Mass. , Oct. 05, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , has appointed John F. Crowley to its Board of Directors. Mr.
